A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors
Anyue Yin,Dirk Jan A.R. Moes,Johan G.C. van Hasselt,Jesse J. Swen,Henk-Jan Guchelaar +4 more
- Vol. 8, Iss: 10, pp 720-737
TLDR
The opportunities of a model‐based approach as discussed in this review can be of great benefit for future optimizing and personalizing anticancer treatment.Abstract:
Increasing knowledge of intertumor heterogeneity, intratumor heterogeneity, and cancer evolution has improved the understanding of anticancer treatment resistance. A better characterization of cancer evolution and subsequent use of this knowledge for personalized treatment would increase the chance to overcome cancer treatment resistance. Model-based approaches may help achieve this goal. In this review, we comprehensively summarized mathematical models of tumor dynamics for solid tumors and of drug resistance evolution. Models displayed by ordinary differential equations, algebraic equations, and partial differential equations for characterizing tumor burden dynamics are introduced and discussed. As for tumor resistance evolution, stochastic and deterministic models are introduced and discussed. The results may facilitate a novel model-based analysis on anticancer treatment response and the occurrence of resistance, which incorporates both tumor dynamics and resistance evolution. The opportunities of a model-based approach as discussed in this review can be of great benefit for future optimizing and personalizing anticancer treatment.read more
Citations
More filters
Posted ContentDOI
Borrowing ecological theory to infer interactions between sensitive and resistant breast cancer cell populations
TL;DR: It is suggested that ecological dynamics change in the presence of therapy, and that an adaptive treatment protocol can induce cycling behavior suggesting that heterogeneous ecological effects contribute to empirically observed adaptive-therapeutic dynamics.
Journal ArticleDOI
Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?
TL;DR: The lack of overall survival benefit in clinical trials of patients with high-risk stage II and stage III disease raises the question of whether it is more efficacious to treat when there is residual microscopic disease, or to wait until the disease recurs.
Journal ArticleDOI
Geometric analysis enables biological insight from complex non-identifiable models using simple surrogates
TL;DR: In this article , the authors study the geometry of a map in parameter space from a complex model to a simple, identifiable, surrogate model, by studying how non-identifiable parameters in the complex model quantitatively relate to identifiable parameters in surrogate.
Posted ContentDOI
Reconstructing tumor trajectories during therapy through integration of multiple measurement modalities
Jason I. Griffiths,Jinfeng Chen,Anne O'Dea,Priyanka Sharma,Onalisa Winblad,Meghna S. Trivedi,Kevin Kalinsky,Kari B. Wisinski,Ruth O'Regan,Issam Makhoul,Laura Spring,Aditya Bardia,Yuan Yuan,Mohammad Jahanzeb,Frederick R. Adler,Adam E. Cohen,Andrea Bild,Qamar Khan +17 more
TL;DR: Tumor trajectory reconstruction integrating multiple modalities of tumor measurement accurately describes tumor progression on therapy and reveals various patterns of patient responses, increasing specificity to distinguish innate or acquired resistance compared to using any single measurement alone.
Posted Content
Optimal control of cytotoxic and antiangiogenic therapies on prostate cancer growth
Pierluigi Colli,Hector Gomez,Guillermo Lorenzo,Gabriela Marinoschi,Alessandro Reali,Elisabetta Rocca +5 more
TL;DR: In this paper, an optimal control framework is proposed to robustly compute the drug-independent cytotoxic and anti-angiogenic effects enabling an optimal therapeutic control of tumor dynamics, and numerical algorithms based on isogeometric analysis are presented to run a preliminary simulation study over a single cycle of combined therapy.
References
More filters
BookDOI
The Case Study
TL;DR: On May 25, 1977, IEEE member, Virginia Edgerton, a senior information scientist employed by the City of New York, telephoned the chairman of CSIT's Working Group on Ethics and Employment Practices, having been referred to the committee by IEEE Headquarters.
Journal ArticleDOI
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan,Charles E. Massie,Javier Garcia-Corbacho,Florent Mouliere,James D. Brenton,Carlos Caldas,Simon Pacey,Richard D. Baird,Nitzan Rosenfeld +8 more
TL;DR: The field is now in an exciting transitional period in which ctDNA analysis is beginning to be applied clinically, although there is still much to learn about the biology of cell-free DNA.
Journal ArticleDOI
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Diaz,Luis A. Diaz,Richard Thomas Williams,Jian Wu,Jian Wu,Isaac Kinde,J. Randolph Hecht,Jordan Berlin,Benjamin L. Allen,Ivana Bozic,Johannes G. Reiter,Johannes G. Reiter,Martin A. Nowak,Kenneth W. Kinzler,Kelly S. Oliner,Bert Vogelstein +15 more
TL;DR: Results suggest that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade and that these mutations can be detected in a non-invasive manner, which explains why solid tumours develop resistance to targeted therapies in a highly reproducible fashion.
Journal ArticleDOI
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Charissa Kim,Ruli Gao,Emi Sei,Rachel Brandt,Johan Hartman,Thomas Hatschek,Nicola Crosetto,Theodoros Foukakis,Nicholas Navin +8 more
TL;DR: The data showed that resistant genotypes were pre-existing and adaptively selected by NAC, while transcriptional profiles were acquired by reprogramming in response to chemotherapy in TNBC patients.
Book ChapterDOI
The Mathematical Model
TL;DR: The death rate per tumor cell due to immunological response is proportional to the total number of antigen-producing (tumor) cells; thus, the total death rate is quadratic.